CHIH-HSIN YANG2020-05-262020-05-2620121556-0864https://www.scopus.com/inward/record.uri?eid=2-s2.0-84865685775&doi=10.1097%2fJTO.0b013e318265a7dc&partnerID=40&md5=75d207826c54a179bfeda26948c63c02https://scholars.lib.ntu.edu.tw/handle/123456789/495056[SDGs]SDG3amrubicin; carboplatin; cisplatin; etoposide; glucuronosyltransferase 1A1; irinotecan; multidrug resistance protein 1; pemetrexed; topotecan; cancer combination chemotherapy; cancer staging; competitive inhibition; correlation analysis; diarrhea; drug dose regimen; drug efficacy; drug metabolism; editorial; genetic variability; genotype; Herpes virus saimiri; human; lung adenocarcinoma; lung small cell cancer; neutropenia; outcome assessment; overall survival; priority journal; progression free survival; single nucleotide polymorphism; treatment response; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Female; Humans; Lung Neoplasms; Male; Small Cell Lung Carcinomaeditorial10.1097/JTO.0b013e318265a7dc228951352-s2.0-84865685775